<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>Treatment of Current (Active) Disease Therapy </title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
</head>

<body>
<div class="uk-container">
    <div>
        <div class="chapter-header">
            <div class="header-title">
                <div>
                    <img src="ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                </div>
                <p class="chapter-title">V. Treatment of Current (Active) Disease Therapy</p>
            </div>
            <p class="last-updated"><i>Last Updated October 2025</i></p>
        </div>
        <hr>
    </div>

    <h4 class="uk-list-title">List of Subchapters</h4>
    
    <ul class="uk-list uk-list-disc">
        <li><a href="5_treatment_of_current_(active)_disease_therapy__a__considerations.html">Considerations</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__b__standard_therapy_for_current_(active)_disease.html" >Standard Therapy for Current (active) Disease</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__c__special_clinical_situations.html">Special Clinical Situations</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__d__drug_resistance.html">Drug Resistance</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__e__monitoring_patients_on_therapy_for_response_and_adverse_events.html">Monitoring Patients on Therapy for Response and Adverse Events</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__f__tb_and_hiv.html">TB and HIV</a></li>
        <!-- <li><a href="5_treatment_of_current_(active)_disease_therapy__g__antiretroviral_therapy_(art)_and_treatment_of_persons.html">Antiretroviral Therapy (ART) and Treatment of Seropositive Patients with Active Tuberculosis</a></li> -->
        <li><a href="5_treatment_of_current_(active)_disease_therapy__h__immune_reconstitution_inflammatory_syndrome.html">Immune Reconstitution Inflammatory Syndrome (IRIS) Associated with Initiation of Antiretroviral Therapy During the Course of TB Therapy</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__i__treatment_of_extrapulmonary_tb.html">Treatment of Extrapulmonary TB</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__j__adjunctive_use_of_corticosteroid_therapy.html">Adjunctive Use of Corticosteroid Therapy</a></li>
    </ul>
    <h4 class="uk-list-title">List of charts</h4>
    <ul class="uk-list uk-list-disc">
        <li><a href="table_7_recommended_regimens_for_treatment_of_adults_and_children_with_drug_susceptible_tb_pulmonary_tb.html">Table 7. Recommended Regimens for treatment of adults and children with Drug Susceptible Pulmonary TB</a></li>
        <li><a href="table_8_first-line_tb_drugs_dosing_for_adults_(ages_16_and_over)_directly_observed_therapy_(dot)_is_mandatory.html">Table 8. First-Line TB Drugs: Dosing for Adults (ages 16 and over) Directly Observed Therapy (DOT) is mandatory</a></li>
        <li><a href="table_9_pediatric_dosage_isoniazid_in_children_(birth_to_15_years).html">Table 9. Pediatric Dosage - Isoniazid in Children (birth to 15 years)</a></li>
        <!-- <li><a href="table_18_dosage_adjustments_for_art_and_rifamycins_when_used_in_combination.html">Table 18. Dosage Adjustments for ART and Rifamycins when used in Combination</a></li> -->
        <li><a href="table_18_grady_hospital_tb_isolation_policy.html">Table 18. Grady Hospital TB Isolation Policy</a></li>
    </ul>
    <h4 class="uk-list-title"> List of Figures </h4>
    <ul class="uk-list uk-list-disc">
        <li><a href="fig1_factors_to_be_considered.html">Figure 1. Factors to be considered in deciding to initiate treatment empirically for active tuberculosis (TB) (prior to microbiologic confirmation)</a></li>
    </ul>
    
</div>
</body>
<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
</html>
